Comentis is engaged in the development of small-molecule drugs designed to either inhibit or enhance angiogenesis, based on the discovery of a new endothelial cell angiogenesis pathway, known as the nAChR pathway. Comentis’s lead products are being developed as oral compounds to treat diseases caused by enhanced angiogenesis, such as cancer and age-related macular degeneration (AMD), as well as topical formulations to treat diseases caused by impaired angiogenesis, such as non-healing wounds. Athenagen plans to introduce two drug candidates into the clinic in 2006: ATG001, an oral anti-angiogenesis compound, for exudative age-related macular degeneration and ATG002, a topical pro-angiogenesis compound, for diabetic foot ulcers.
Financials
| Date | Type | Amount | Investors | Valuation |
|---|---|---|---|---|
| 06/05/08 | Series D | 20M | Unknown |
People
Ken Kengatharan (VP pre-clinical research and development)
John Hey (VP Non-clinical Development)
Carl Grove (VP Development Operations & Regulatory Affairs)
Griffin Murray (VP Corporate Finance)
John Cooke (VP Scientific Officer)
News
CoMentis raises $20 million for Alzheimer's drugs
June 5, 2008 12:00 pm
CoMentis has raised $20 million in a fourth round of funding to create drugs to fight Alzheimer’s disease, age-related macular… Continue reading ⟩
CoMentis gets $12M for eye, Alzheimer’s treatments
December 3, 2007 6:46 pm
See our story on this South San Francisco, Calif., biotech in today’s daily briefing at VentureBeat Life Sciences. Continue reading ⟩
Life sciences briefing: Monday, Dec. 3, 2007
December 3, 2007 4:33 pm
Featured companies: CoMentis, ForHealth Technologies, Merrimack Pharmaceuticals, QuantomiX, Progenitor Cell Therapy, River Diagnostics, Topaz Pharmaceuticals UPDATED: Expanded items on CoMentis,… Continue reading ⟩